



## **Supporting Information**

### **Full guidelines**

**This appendix was part of the submitted manuscript and has been peer reviewed.  
It is posted as supplied by the authors.**

Appendix to: Chiew AI, Reith D, Pomerleau A, et al. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. *Med J Aust* 2019; doi: 10.5694/mja2.50428.

## Consensus statement

# Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand — explanation and elaboration

Chiew AL<sup>1,2,3</sup>, Reith DM<sup>4</sup>, Pomerleau AC<sup>5</sup>, Wong A<sup>6,7,8</sup>, Isoardi KZ<sup>9,10</sup>, Soderstrom J<sup>11,12,13</sup>, Buckley NA<sup>2,3</sup>

<sup>1</sup> Clinical Toxicology, Prince of Wales Hospital, Randwick, NSW, Australia.

<sup>2</sup> NSW Poisons Information Centre, Children's Hospital at Westmead, Westmead, NSW, Australia.

<sup>3</sup> Pharmacology, Faculty of Medicine and Health, University of Sydney, Australia.

<sup>4</sup> Otago School of Medicine, University of Otago, Dunedin, Otago, New Zealand.

<sup>5</sup> National Poisons Centre, University of Otago, Dunedin, New Zealand.

<sup>6</sup> Victorian Poisons Information Centre, Austin Toxicology Unit and Emergency Department, Austin Health, Victoria, Australia.

<sup>7</sup> Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia.

<sup>8</sup> Centre for Integrated Critical Care, Department of Medicine and Radiology, Melbourne Medical School, University of Melbourne, Victoria, Australia.

<sup>9</sup> Clinical Toxicology Unit, Princess Alexandra Hospital, Woolloongabba, Australia.

<sup>10</sup> Queensland Poisons Information Centre, Queensland Children's Hospital, South Brisbane, Australia.

<sup>11</sup> Clinical Toxicology, Royal Perth Hospital, Perth, Western Australia, Australia

<sup>12</sup> WA Poisons Information Centre, Perth, Western Australia, Australia.

<sup>13</sup> University of Western Australia, Faculty of Health and Medical Sciences, Perth, Western Australia, Australia.

E-mail: angela.chiew@health.nsw.gov.au

Published: December 2019

## Abstract

### Introduction:

Paracetamol is a very common agent taken in deliberate self-poisoning, and a common agent in accidental overdoses in adults and children. Paracetamol poisoning is the most common cause of severe acute liver injury. Since previous guidelines were published in the MJA in 2015, several studies have changed practice. A working group of experts in the area with representation from all Poisons Information Centres of Australia and New Zealand were brought together to produce an updated evidence-based guidance.

### Main recommendations (unchanged from previous guidelines):

- The optimal management of most patients with paracetamol overdose is usually straightforward. Patients who present early should be given activated charcoal. Patients at risk of hepatotoxicity should receive intravenous acetylcysteine.
- The paracetamol nomogram is utilised to assess need for treatment in acute immediate-release paracetamol ingestions with a known time of ingestion.
- Cases which require a different management pathway include modified-release paracetamol overdoses, large/massive overdoses, accidental liquid ingestion in children, and repeated supra-therapeutic ingestions (e.g. excessive use of paracetamol as an analgesic).

### Major changes in management in the guideline:

- The new guidelines recommend a two-bag acetylcysteine infusion regimen (200 mg/kg over 4 h, then 100 mg/kg over 16 h). This has similar efficacy but significantly reduced adverse reactions (compared to the previous 'three-bag' regimen).
- "Massive" paracetamol overdoses which result in high paracetamol concentrations more than double the nomogram line should be managed with an increased dose of acetylcysteine.
- All potentially toxic modified-release paracetamol ingestions ( $\geq 10$  g or 200 mg/kg whichever is less) should receive a full course of acetylcysteine. Those who ingest  $\geq 30$  g or  $\geq 500$  mg/kg should receive increased doses of acetylcysteine. These patients having a higher risk of acute liver injury and may need repeated tests and prolonged therapy.

**Keywords:** paracetamol, guideline, poisoning, overdose

## Introduction

Paracetamol is one of the commonest drugs taken in overdoses, leading to hospital presentation and admission and is the commonest cause of severe acute liver injury in Western countries [1, 2]. Fortunately, hepatic failure and death are uncommon outcomes [1, 2]. Paracetamol poisoning is also the most common reason for calls to Poisons Information Centres

in Australia and New Zealand [3]. Not only is it one of the commonest medications involved in deliberate self-poisoning, it is also involved in a large proportion of accidental paediatric exposures, and overdoses with therapeutic intent when taken for symptoms such as pain or fever (repeated supratherapeutic ingestions).

Since the previous guidelines were published in the MJA in 2015, further research has emerged particularly regarding

acetylcysteine regimens, massive paracetamol ingestions and modified release paracetamol ingestion. These have led to a change in management of paracetamol poisoning and the 2015 guidelines do not reflect the current practice recommended by clinical toxicologists. This guideline details management for paracetamol poisoning in all these situations. The key changes from the previous guidelines are acetylcysteine regimen (two bag regimen) and dosage, management of patients taking large/massive overdoses, staggered ingestions, modified-release paracetamol ingestions and repeated supratherapeutic ingestion (RSTI).

## Methods

The Treatment of Paracetamol Poisoning Writing Group comprised of Clinical Toxicologists and Pharmacologists from Australia and New Zealand. All members completed a detailed literature review and critically appraised existing evidence, including reviewing the relevant chapters from the newly updated Australian Therapeutic Guidelines: Toxicology & Toxinology [4]. Drafts of evidence-based recommendations, practice points and background manuscript were developed. We conducted a face-to-face meeting in May 2019 to draft the guideline. Further revisions were made via email and teleconference. The summary recommendations follow the National Health and Medical Research Council levels of evidence ([www.mja.com.au/acs.hcn.com.au/sites/default/files/NHMR\\_C.levels.of.evidence.2008-09.pdf](http://www.mja.com.au/acs.hcn.com.au/sites/default/files/NHMR_C.levels.of.evidence.2008-09.pdf)) and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system ([www.gradeworkinggroup.org](http://www.gradeworkinggroup.org)) to determine the strength of the recommendations.

## Recommendations

Acute deliberate self-poisoning, accidental paediatric exposure and inadvertent repeated supratherapeutic ingestions all require specific approaches to risk assessment and management.

The initial approach focuses on risk assessment (**Box 1**); key factors to consider for paracetamol poisoning are the formulation and dose ingested, time since ingestion and serum paracetamol concentration (early), or clinical and laboratory features suggesting acute liver injury (late). Serum paracetamol concentration(s) should be used to assess the need for acetylcysteine administration in all patients presenting with deliberate self-poisoning with paracetamol, regardless of the stated dose.

We have summarised with flow charts the management of acute paracetamol exposure with known time of ingestion (**Flowchart 1**), modified release (**Flowchart 2**) and repeated supra-therapeutic ingestion (**Flowchart 4**). We have also developed a flowchart for the management of acute paracetamol poisoning for centres with limited resources (**Flowchart 3**).

Where there are any concerns regarding the management of paracetamol ingestion advice can always be sought from a clinical toxicologist or Poisons Information Centre (13 11 26 in Australia, 0800 764 766 in New Zealand).

### Box 1: Paracetamol dosing that may be associated with acute liver injury.

<b>Acute Single Ingestion *</b>	≥ 10 g or ≥ 200 mg/kg (whichever is less)
<b>Repeated Supra-therapeutic Ingestion (RSTI) #</b>	≥ 10 g or ≥ 200 mg/kg (whichever is less) over a single 24-hour period. OR ≥ 12 g or ≥ 300 mg/kg (whichever is less) over a single 48-hour period. OR ≥ a daily therapeutic dose <sup>^</sup> per day for more than 48 hours in those who also have abdominal pain or nausea or vomiting.

\*Acute ingestion is defined as any intentional/ deliberate paracetamol overdose, including staggered or multiple paracetamol ingestions over more than 2 hours.

# Repeated supra-therapeutic ingestion is any patient who ingests paracetamol for therapeutic intent. These doses are a guide for asymptomatic patients at risk for acute liver injury. All symptomatic patients should be assessed with a paracetamol concentration and ALT.

<sup>^</sup> Therapeutic daily dose of paracetamol in adults is a total dose of 60 mg/kg over 24 hours and up to a maximum dose of 4 g/day. For paediatric dosage refer to local guidelines.

## Background: Paracetamol kinetics

Paracetamol is rapidly absorbed from the small intestine. In therapeutic doses, peak serum concentrations occur within 1–2 hours for standard tablet or capsule formulations and within 30 minutes for liquid preparations. Peak serum concentrations after therapeutic doses do not usually exceed 20 mg/L (132 µmol/L). Twenty per cent of the ingested dose undergoes first-pass metabolism in the gut wall (sulphation). Distribution is usually within 4 hours of ingestion for standard preparations and 2 hours for liquid preparations [5, 6].

In therapeutic doses, the elimination half-life is 1.5–3 hours. About 90% is metabolised to inactive sulphate and glucuronide conjugates that are excreted in the urine. Metabolism of the remainder is via cytochrome P450 enzymes (chiefly CYP2E1 and CYP3A4) and results in the highly reactive intermediary compound N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is detoxified by irreversible glutathione-dependent conjugation reactions to mercapturic acid and cysteine conjugates [7, 8]. In overdose, the increased formation of NAPQI depletes hepatic glutathione stores and NAPQI covalently binds to critical cellular proteins [9], causing damage to hepatocytes and acute liver injury.

## Management of acute paracetamol ingestion

Acute paracetamol ingestion refers to any deliberate or intentional ingestions of paracetamol usually for the purpose of self-harm. This ingestion may be a single ingestion over less than 2 hours or staggered or multiple ingestions over greater than 2 hours (see [Multiple or “Staggered” Immediate-Release Paracetamol Ingestions](#)). Those patients who ingest extra doses of paracetamol for therapeutic intent (e.g. pain such as toothache, back pain or flu symptoms) should be managed as per repeated suprathreshold ingestion (see [Repeated Suprathreshold Ingestion](#)).

### Risk assessment

A risk assessment, in which the clinician attempts to predict the most likely clinical course and potential complications of the patient’s presentation, should occur as soon as possible in the management of all poisoned patients. The key factors to consider for paracetamol poisoning are:

- Ingested dose ([Box 1](#))
- Time of ingestion
- Preparation ingested (e.g. immediate-release or modified-release)
- Single or staggered ingestion

The most important risk factor for liver damage and death after acute paracetamol ingestion is the time before treatment with acetylcysteine commences. Treatment started within 8 hours will prevent serious hepatic injury, in almost all patients [10].

Key investigations for the management of an acute paracetamol ingestion are shown in [Box 2](#). All patients who present with paracetamol self-poisoning regardless of the stated dose should be assessed with a serum paracetamol concentration and alanine aminotransferase (ALT). These results are utilised to guide management, the serum paracetamol concentration is utilised in conjunction with the paracetamol treatment nomogram in those presenting within 24 hours post-ingestion. The initial ALT helps guide management in those presenting greater than 8 hours post-ingestion. An ALT is now suggested to be taken in all patients including those presenting within 8 hours post-ingestion, as in these patients it will serve as a baseline. Clinical or biochemical evidence of liver injury may not be apparent for up to 24 hours after acute paracetamol overdose.

### Box 2: Recommended investigations for acute immediate and modified release paracetamol ingestion according to time from ingestion to acetylcysteine treatment.

Time (hours) from paracetamol ingestion to acetylcysteine	Investigations on admission	Investigations at the completion of acetylcysteine
Less than 24 hours	ALT and serum paracetamol concentration	ALT*
Greater than 24 hours	Serum paracetamol concentration, ALT and INR <sup>#</sup>	ALT and INR <sup>#</sup>
Patients who have an abnormal ALT	UEC, LFTs, INR, BSL, phosphate and VBG (looking at the pH and lactate).	<b>Repeat investigations every 12 hours including:</b> UEC, LFTs, INR, BSL and VBG (looking at the pH and lactate).

ALT = alanine aminotransferase, BSL = blood sugar level, INR = international normalised ratio, UEC = urea, electrolytes, creatinine, VBG = venous blood gas.

#### NOTE:

\* If initial paracetamol concentration was  $\geq$  double the nomogram line (e.g. 300 mg/L at 4 h) or modified-release preparation ingested, then repeat paracetamol concentration at the completion of acetylcysteine.

<sup>#</sup> A mild elevation in international normalised ratio (INR) no greater than 2.0, may occur early in those without hepatic injury. This is due to direct inhibition of clotting factor production and activity, by paracetamol and acetylcysteine, respectively.[11-13]

## Paracetamol treatment nomogram


The paracetamol treatment nomogram ([Figure 1: Rumack–Matthew nomogram](#)) is used to decide whether to start or continue acetylcysteine therapy. Acute liver injury can occur if a patient's serum paracetamol concentration is above the nomogram line. The current nomogram for assessing requirement to treat paracetamol overdose has been used in Australia since 2008 [14]. The paracetamol treatment nomogram has been validated as an excellent predictor of risk, but only for acute ingestions of immediate release paracetamol with a known time of ingestion. The efficacy and safety of dosing acetylcysteine according to the Rumack–Matthew nomogram has been demonstrated in a study of more than 11,000 patients, with no deaths among patients who were below the line, or above the line and treated within 15 hours [15].

The nomogram cannot be applied in those presenting more than 24 hours post ingestion or if the time of ingestion cannot be determined with confidence by the treating clinician, or in

modified-release or supratherapeutic ingestions. The current nomogram utilised in Australia and New Zealand has not changed (Figure 1). It is important to check the units utilised with many laboratories recently changing from  $\mu\text{mol/L}$  to  $\text{mg/L}$ . As most laboratories utilise  $\text{mg/L}$  these units now appear on the left axis, previously in the 2015 guidelines they appeared on the right.

The 150  $\text{mg/L}$  (1000  $\mu\text{mol/L}$ ) at 4 hours nomogram is currently used in the USA, Canada, Australia and New Zealand. This contrasts with the United Kingdom that utilises a lower nomogram treatment line of 100  $\text{mg/L}$  (660  $\mu\text{mol/L}$ ) at 4 hours. This has resulted in tens of thousands of very low risk patients in the UK receiving acetylcysteine exposing them to the risks of treatment and increasing rates of hospital admissions at a very substantial cost [16, 17].

*GRADE: Strong; Evidence: Strong.*



**Figure 1: Paracetamol Treatment Nomogram (Rumack-Matthew Nomogram)**

*Note:  $\mu\text{mol/L}$  = micromol/L = nmol/mL*

## General Management: Resuscitation

Immediate threats to the airway, breathing and circulation are extremely rare in isolated paracetamol overdose. In exceptional cases, massive ingestion causing extremely high serum paracetamol concentrations (usually above 800 mg/L or > 5000 µmol/L) may be associated with an early decrease in level of consciousness and lactic acidosis [18]. This is secondary to a direct mitochondrial effect, rather than hepatotoxicity. Supportive management is appropriate in such cases; acetylcysteine is the mainstay of treatment. For specific treatment see section on [“large/massive” paracetamol ingestion](#). Haemodialysis has been described in this setting for severe metabolic acidosis but is not generally required; clinical toxicology advice should be sought if this is considered.

Any alteration of conscious state should prompt bedside testing of the patient’s serum glucose level and correction of hypoglycaemia, if present. This is only likely to be due to paracetamol if there is hepatic failure.

## Gastrointestinal decontamination

Activated charcoal (50 g in an adult) is recommended in awake and cooperative patients in the following ingestions:

- Within 2 hours of ingesting a toxic dose of paracetamol [ $\geq 10$  g or  $\geq 200$  mg/kg (whichever is less)].
- Within 4 hours of ingesting  $\geq 30$  g of immediate-release paracetamol (see [large/massive paracetamol overdose](#)).
- Within 4 hours of ingesting a toxic dose [ $\geq 10$  g or  $\geq 200$  mg/kg (whichever is less)] of modified-release paracetamol. Note in larger overdoses activated charcoal may be indicated up to 24 hours post-ingestion.

Activated charcoal administered within 2 hours of an immediate release paracetamol ingestion reduces the absorbed paracetamol dose and the likelihood that acetylcysteine will subsequently be required [19, 20]. In those who ingest greater than 30 g of paracetamol, activated charcoal within 4 hours of ingestion is associated with a reduced risk of acute liver injury [21].

Modified-release paracetamol ingestions, particularly large doses, may result in prolonged and erratic paracetamol absorption [22, 23]. Activated charcoal should be administered for up to 4 hours post-ingestion and even longer in larger overdoses (see [Modified-release paracetamol overdose](#)) [22].

Nevertheless, if activated charcoal cannot be administered, treatment with acetylcysteine within 8 hours guarantees survival in almost all cases. Therefore, activated charcoal alone is not a life-saving treatment that may be imposed under a duty-of-care principle.

Significant hepatic injury is extremely rare after acute single accidental paracetamol ingestion in children under 6 years of age, and it is very uncommon for them to have concentrations that require acetylcysteine treatment. Therefore, gastrointestinal decontamination with activated charcoal is not indicated in children under 6 years of age, even if they might have ingested a toxic dose of paracetamol.

*GRADE: Strong; Evidence: Low.*

## Management of immediate release paracetamol overdose

The management of an acute immediate release paracetamol ingestion (defined as any intentional or deliberate self-poisoning) is summarised in [Flowchart 1](#). Management is dependent on time post-ingestion and if the ingestion was single or staggered.

### A. Acute immediate release paracetamol exposure with known time of ingestion

Treatment with acetylcysteine ensures survival if administered within 8 hours of paracetamol ingestion [15, 24]. Beyond 8–10 hours after ingestion, efficacy decreases with increasing delay to treatment [15]. If the result of a paracetamol concentration can be obtained within 8 hours of ingestion, acetylcysteine administration may be delayed until a serum paracetamol concentration plotted on the nomogram confirms it is indicated. This is provided treatment can still be commenced within the 8-hour window if it is required. Supplementary investigations such as liver function tests or a coagulation profile do not refine the initial risk assessment or change management in this group. However, a baseline ALT is performed for comparison to the ALT at the completion of acetylcysteine.


If a paracetamol concentration cannot be obtained until 8 or more hours after ingestion, acetylcysteine should be commenced immediately if the reported dose exceeds the threshold for possible toxicity ([Box 1](#)), or the patient shows clinical signs suggestive of paracetamol hepatotoxicity (nausea, vomiting, right upper quadrant pain or tenderness). Evaluation of serum paracetamol concentration and ALT should then be performed as soon as possible. If the serum paracetamol concentration is subsequently found to be below the nomogram line and ALT concentration is  $\leq 50$  U/L, acetylcysteine may be ceased. If the paracetamol concentration is above the line OR ALT  $> 50$  U/L (and increasing if baseline ALT  $> 50$  U/L), acetylcysteine should be continued.

There is a small (< 1%) risk of patients developing acute liver injury despite having a paracetamol concentration below the 150 mg/L (1000 µmol/L) at 4 hours nomogram line. Hence patients not given acetylcysteine should be advised to return for further assessment if they develop abdominal pain, nausea or vomiting after discharge.

### B. Large/massive paracetamol ingestion

Most patients ingest less than 30 g of paracetamol. The majority of those given acetylcysteine have paracetamol concentrations just above the treatment nomogram line [20, 25]. A small percentage of patients, usually ingesting  $\geq 30$  g, have a high initial paracetamol concentration greater than double the nomogram line and are at increased risk of acute liver injury if given standard acetylcysteine regimens (300 mg/kg of acetylcysteine over 20 h) [21, 26, 27]. In some studies, 5–7% of these patients will still develop hepatotoxicity despite being treated within 8 hours with acetylcysteine [15, 28]. This risk of acute liver injury increases with increasing paracetamol concentrations [27]. In patients with high paracetamol concentrations, the standard acetylcysteine regimen is not adequate to detoxify increasing amounts of

### Flowchart 1: Acute Immediate Release Paracetamol Ingestion Management Flowchart



NAPQI produced in large overdoses and hence higher doses of acetylcysteine are warranted [29, 30].

Those with an initial paracetamol concentration greater than double the nomogram line have been shown to benefit from an increased dose of acetylcysteine [21]. The second bag in the two-bag acetylcysteine regimen should be doubled to 200 mg/kg IV acetylcysteine over 16 hours (instead of 100 mg/kg over 16 hours) ([Box 3](#)). Patients with even higher concentrations (e.g.  $\geq$  triple the nomogram line) may benefit from even higher acetylcysteine doses [29, 30]. These patients should be discussed with a clinical toxicologist or Poisons Information Centre.

*GRADE: Strong; Evidence: Low.*

### **C. Multiple or “staggered” immediate-release paracetamol ingestion**

This covers any staggered or multiple paracetamol ingestions over more than 2 hours for the purpose of deliberate self-harm. This is distinct from repeated-supratherapeutic ingestion which is ingestion of excessive paracetamol for therapeutic purposes ([Flowchart 4](#)). Staggered ingestions should be treated as per acute immediate release ingestion ([Flowchart 1](#)) utilising the earliest time of ingestion for the paracetamol nomogram. Hence, if it is more than 8 hours since the first dose of paracetamol or the paracetamol concentration cannot be obtained within 8 hours, then commence acetylcysteine. If the first paracetamol concentration was measured within 2 hours of the last ingested paracetamol dose it should be repeated after 2 hours to ensure there is no ongoing absorption. If either concentration is above the nomogram line (using time from the earliest ingestion), start/continue treatment with acetylcysteine.

*GRADE: Weak; Evidence: Very low.*

### **D. Acute paracetamol exposure with unknown time of ingestion**

If the time of ingestion is unknown, or the treating clinician is not confident of the history of ingestion, it is safest to treat the patient as a delayed presentation. Thus, the recommendation is to follow the  $> 8$  hours scenario in [Flowchart 1](#); that is to commence acetylcysteine. If the serum paracetamol concentration is greater than 10 mg/L (66  $\mu$ mol/L) or the ALT is  $> 50$  U/L, acetylcysteine treatment should be continued.

If further history becomes available and the serum paracetamol concentration can be accurately plotted on the nomogram, this should be done, and acetylcysteine discontinued if the paracetamol concentration is below the treatment line.

### **Investigations near the completion of acetylcysteine for acute immediate release ingestion and criteria for ongoing acetylcysteine:**

Near the completion of acetylcysteine (i.e. 2 hours before completion of the infusion), ALT should be repeated in all patients. For those with an initial paracetamol greater than

double the nomogram line a paracetamol concentration should also be repeated. Acetylcysteine should be continued if the paracetamol concentration is  $> 10$  mg/L (66  $\mu$ mol/L) or ALT is elevated ( $> 50$  U/L) and increasing (if baseline ALT  $> 50$  U/L). Small fluctuations in ALT (e.g.  $\pm 20$  U/L or  $\pm 10\%$ ) are common and do not on their own indicate the need for ongoing acetylcysteine.

This is a change from previous guidelines, where ALT was only repeated in those commencing acetylcysteine  $\geq 8$  hours post ingestion and those with a high initial paracetamol concentration. ALT should be measured in all patients at the completion of acetylcysteine as there is a small ( $< 1\%$ ) risk of developing acute liver injury despite treatment with acetylcysteine within 8 hours [27, 29, 31, 32].

*GRADE: Strong; Evidence: Low.*

### **Acute modified-release paracetamol ingestion**

Modified-release paracetamol contains 69% modified-release and 31% immediate-release paracetamol in a 665 mg tablet. In the last guidelines, management was very similar to that for immediate-release paracetamol. However, evidence from studies and case series from both Australia and Europe have shown that this approach appears inadequate [22, 23, 33]. A recent observational study from Australia found that following an acute overdose of modified-release paracetamol patients may have persistently high paracetamol concentrations, double paracetamol peaks, and ongoing absorption [22]. Many patients required prolonged acetylcysteine treatment and treatments such as activated charcoal and increased acetylcysteine did not appear to substantially mitigate the risk of acute liver injury [22]. Hence the recommended management has changed considerably ([Flowchart 2](#)).


All modified-release paracetamol overdose (including mixed ingestion of immediate and modified release paracetamol) of  $\geq 10$  g or 200 mg/kg (whichever is less) should be offered activated charcoal up to 4 hours post-ingestion. For massive ( $\geq 30$  g) modified-release paracetamol overdoses, absorption may continue up to 24 hours post-ingestion; patients may benefit from activated charcoal beyond 4 hours [22].

The nomogram should not be used to assess need for treatment of potentially toxic modified-release ingestions. Paracetamol concentrations are useful to guide further management such as acetylcysteine dosage (e.g. the need for increased or prolonged treatment) and need for further decontamination (e.g. further doses of activated charcoal if paracetamol concentrations remain unchanged or rise). Importantly, all those who ingest  $\geq 10$  g or 200 mg/kg (whichever is less) should immediately commence acetylcysteine ([Flowchart 2](#)) and receive a full 20 hour course of acetylcysteine regardless of their serum paracetamol concentration(s).

All patients who ingest  $\geq 30$  g or  $\geq 500$  mg/kg of modified release paracetamol or have a paracetamol concentration greater than double the nomogram line should receive an increased dose of acetylcysteine.



## Flowchart 2: Acute Ingestion Modified-Release Paracetamol Management Flowchart



The second bag in the current standard IV acetylcysteine regimen should be doubled to 200 mg/kg IV acetylcysteine over 16 hours. This is because the majority of the preparation is modified-release and initial paracetamol concentrations may only reflect the immediate-release component of the preparation. Hence, following large MR paracetamol ingestions acetylcysteine doses may be inadequate due to ongoing paracetamol absorption.

Those who report ingesting less than a toxic dose (< 10 g AND < 200 mg/kg) should have two serum paracetamol concentrations 4 hours apart, starting at least 4 h post-ingestion. If either is above the nomogram line, a standard course of acetylcysteine should be given.

Acetylcysteine is often required for much longer durations. ALT and a paracetamol concentration should be checked near the completion of the second bag of acetylcysteine.


Acetylcysteine should be continued if the paracetamol concentration is  $\geq 10$  mg/L (66  $\mu$ mol/L) OR ALT is elevated ( $> 50$  U/L) and increasing (if baseline ALT  $> 50$  U/L). Small fluctuations in ALT (e.g.  $\pm 20$  U/L or  $\pm 10\%$ ) are common and don't on their own indicate the need for ongoing acetylcysteine. Higher doses of acetylcysteine may be required in subsequent infusions if the paracetamol concentration remains  $\geq 100$  mg/L (660  $\mu$ mol/L) and further advice should be sought.

GRADE: Strong; Evidence: Very low.

### Rural and Remote Centres

Many rural and remote health care facilities do not have access to 24-hour pathology or have very limited pathology (e.g. point of care testing only). These facilities can still manage

**Flowchart 3: Acute Immediate Release Paracetamol Ingestion Management Flowchart for Rural/ Remote Facilities^ (no pathology availability)**




**Note:** This flowchart applies to facilities that **do not** have the capacity to measure a paracetamol concentration and/or ALT but are able to administer IV acetylcysteine. All other facilities should follow [Flowchart 1: Immediate Release Paracetamol Ingestion Management Flowchart](#).

Patients who have ingested modified release paracetamol overdoses  $\geq 10$  g or  $\geq 200$  mg/kg (whichever is less) should have activated charcoal and acetylcysteine started and transfer arranged.

\*For acetylcysteine regimen see Box 3

# These patients are at increased risk of acute liver injury and so require further assessment at a hospital that has pathology services.

### Flowchart 4: Repeated Supratherapeutic Ingestion Management Flowchart



acute paracetamol poisoning provided acetylcysteine is available (Flowchart 3). As a paracetamol concentration is not easily available in these facilities the need for acetylcysteine is based on ingested dose and the time of ingestion < 8 hours. Patients at high risk of acute liver injury (e.g. acetylcysteine > 8 hours post-ingestion, symptomatic or large ingestions [ $\geq$  30 g]) require transfer to a larger facility with pathology capabilities. Patients who have ingested a toxic dose of modified release paracetamol overdoses should have activated charcoal and acetylcysteine commenced and transfer arranged.

## Paediatric (< 6 years) liquid paracetamol ingestion

Paediatric patients (children < 6 years) are thought to be less susceptible to paracetamol toxicity than older children and adults [34]. Furthermore, they usually present with accidental liquid paracetamol ingestions. Young children who ingest liquid paracetamol have rapid absorption and an earlier time to peak paracetamol concentration because of shorter elimination half-lives. Activated charcoal is not indicated in this group as liquid preparations have rapid absorption.

In children less than 6 years of age, where ingestion of greater than 200 mg/kg of liquid paracetamol is suspected, a serum paracetamol concentration should be measured at least 2 hours post-ingestion [35]. If the 2 (to 4) hour concentration is below 150 mg/L (1000  $\mu$ mol/L), acetylcysteine is not required. If the 2-hour paracetamol concentration is greater than 150 mg/L (1000  $\mu$ mol/L), this should be repeated 4 hours post-ingestion and acetylcysteine commenced if this is  $\geq$  150 mg/L (1000  $\mu$ mol/L).

A 2-hour concentration should only be utilised in a well-child < 6 years of age with an isolated liquid paracetamol ingestion. In all other cases a 4-hour concentration should be performed. Further, for those children who present later than 4 hours post-ingestion or in children older than 6 years of age, treatment is as per the adult acute paracetamol exposure guideline.

*GRADE: Strong; Evidence: Very low.*

## Repeated supra-therapeutic ingestion (RSTI)

Patients who ingest excessive paracetamol for a therapeutic purpose (e.g. pain, viral illness) or ingest therapeutic doses of paracetamol and have symptoms of acute liver injury (e.g. abdominal pain, nausea and vomiting) are managed as RSTI (Flowchart 4).

If the ingestion is deliberate/intentional they should be managed as per acute intentional ingestion. There is little evidence to guide risk assessment for repeated ingestion of high doses of paracetamol. The margin of safety has for many years been assumed to be high [36]. Minor subclinical elevations of serum ALT are quite common with prolonged therapy [37]. However, hepatotoxicity has been reported at doses within the therapeutic range of paracetamol (in some cases at doses less than the recommended 4 g/day). The reasons why certain individuals are at greater risk of toxicity are unclear [38], but toxicity could be influenced by age,

comorbidities, alcohol use, nutritional status (e.g., prolonged fasting), concurrent medicine use and genetics. Some patients are likely to be at increased risk for acute liver injury following RSTI due to glutathione depletion or CYP450 induction. Clinical flags would include pregnancy, prolonged fasting, chronic alcoholism, febrile illness and chronic use of CYP450 inducing drugs such as carbamazepine [39]. Hence, the threshold for potentially toxic dose has been made deliberately and conservatively low in this and previous guidelines.

Those patients who meet the criteria for supratherapeutic ingestion (Box 1) should have a paracetamol concentration and ALT measured. There is evidence that the combination of a low paracetamol concentration and normal ALT at any time indicates there is minimal risk of subsequent hepatotoxicity [40-42]. If the paracetamol concentration is > 20 mg/L (132  $\mu$ mol/L) or ALT > 50 U/L, then acetylcysteine is commenced, and pathology repeated 8 hours after the initial sampling. Those with significant acute liver injury secondary to paracetamol will have a very high and/or rapidly rising ALT [41, 43]. Small fluctuations in ALT (e.g. +/- 20 U/L or +/- 10%) are common and do not on their own indicate the need for ongoing acetylcysteine. All patients with an initial ALT > 1000 U/L should receive at least a full 20 h course of IV acetylcysteine.

*GRADE: Strong; Evidence: Very low.*

## Acetylcysteine

Acetylcysteine is an effective antidote and should be administered to all patients judged to be at risk of developing hepatotoxicity after paracetamol overdose. With acetylcysteine therapy, morbidity from overdose can be minimised. Oral acetylcysteine and methionine have also been used to prevent hepatotoxicity [24, 44]. Neither is registered for use in Australasia and the oral regimens often provoke vomiting.

Acetylcysteine reduces mortality if commenced in late presenting patients with established paracetamol-induced fulminant hepatic failure, although mechanisms of action in this period may be different. In this setting, acetylcysteine reduces inotrope requirements, decreases cerebral oedema and increases the rate of survival by about 30% [45].

### A. Acetylcysteine infusions

The standard (traditional) three-bag intravenous (IV) weight-based acetylcysteine dosage regimen (150 mg/kg body weight over 15-60 minutes, then 50 mg/kg over 4 hours and 100 mg/kg over 16 hours [300mg/kg total]) was developed in the 1970's. It was empirically derived and not subject to dose ranging studies [29]. This regimen has proven to be highly efficacious when compared to no treatment but causes frequent adverse reactions and the dosing regimen is complex and prone to error [10, 46]. Various acetylcysteine dosing regimens have been proposed and studied worldwide with the aim to decrease the rate of adverse effects [46]. These regimens include the Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning (SNAP) 12-hour regimen and the two-bag acetylcysteine protocol. Both have

shown to decrease the rate of adverse events [47-50], with similar efficacy to the standard regimen [51, 52].

A two-bag acetylcysteine regimen ([Box 3](#)) will now replace the three-bag regimen recommended in previous guidelines. The two-bag acetylcysteine regimen slows the initial loading dose and simplifies the protocol (i.e. 200mg/kg over 4 hours followed by 100 mg/kg over 16 hours). This is widely used in toxicology units around Australia and has been shown to significantly reduce the rates of adverse reactions [48-50, 52, 53].

Acetylcysteine is packaged for intravenous infusion in ampoules, each containing a 20% solution (i.e. 200 mg acetylcysteine per 1 mL). Prescription of acetylcysteine requires a two-stage calculation to compute the appropriate weight-based dose and then the volume required. Calculation or transcription errors may lead to potentially fatal dosing errors. It is recommended that dosing tables providing the required dose and volume of 20% acetylcysteine by weight, are used to chart each infusion. This precludes the need for calculations and decreases the potential for error ([Box 4](#)). Furthermore, it is also important to ensure adequate mixing of acetylcysteine and fluid when preparing the infusion [54].

Calculation of acetylcysteine doses is based on actual bodyweight rounded up to the nearest 10 kg, but with a ceiling weight of 110 kg [55]. For children, the dose of acetylcysteine is calculated in the same way, but with the volume reduced appropriately ([Box 3](#)).

GRADE: Strong; Evidence: low.

### B. Acetylcysteine Adverse Reactions

Non-IgE mediated anaphylactic (anaphylactoid) reactions manifested by rash, wheeze or mild hypotension occurred in 10%–50% of patients administered the traditional three bag IV

acetylcysteine regimen [56-58]. With a two-bag regimen this rate is significantly lower (~5%) [48, 50]. Management of these reactions is supportive, with temporary halting or slowing of the infusion and administration of antihistamines and bronchodilators if required [59]. The occurrence of a non-IgE mediated anaphylactic reaction does not preclude the use of acetylcysteine on another occasion if indicated. Severe life-threatening reactions are very rare and should be treated with adrenaline as required. Once symptoms settle acetylcysteine can be recommenced. Reactions are more likely to occur in predisposed individuals, such as patients with asthma [60].

### C. Cessation of Acetylcysteine

Some patients will require ongoing treatment with acetylcysteine if they have a persistently high paracetamol concentration > 10 mg/L (66 µmol/L) or if the ALT is > 50 U/L and increasing. [note: small fluctuations in ALT (e.g. +/- 20 U/L or +/-10%)] are common and do not on their own indicate the need for ongoing acetylcysteine). In these cases, acetylcysteine should be continued until the patient has met all the criteria outlined in [Box 5](#). Acetylcysteine is generally continued at the rate of the second infusion (e.g. 100 mg/kg over 16 hours) ([Box 3](#)). Higher infusion rates may be warranted for massive paracetamol ingestions, especially if the paracetamol concentration is ≥ 100 mg/L (660 µmol/L) at the completion of the initial acetylcysteine infusion; a clinical toxicologist should be consulted in such cases. Regular clinical review and at least 12 hourly blood tests are recommended for those requiring prolonged treatment ([Box 2](#)).

GRADE: Strong; Evidence: low

### Box 3: Standard Two-Bag Acetylcysteine Regimen<sup>#^</sup>

#### Initial Infusion:

*acetylcysteine 200 mg/kg (maximum 22 g) in glucose 5% 500 mL (child 7 mL/kg up to 500 mL) or sodium chloride 0.9% 500 mL (child 7 mL/kg up to 500 mL) intravenously, over 4 hours.<sup>^</sup>*

#### Second acetylcysteine infusion:

*acetylcysteine 100 mg/kg (maximum 11 g) in glucose 5% 1000 mL (child 14 mL/kg up to 1000 mL) or sodium chloride 0.9% 1000 mL (child 14 mL/kg up to 1000 mL) intravenously, over 16 hours.<sup>^\*</sup>*

**If ongoing acetylcysteine is required, continue at the rate of the second infusion (e.g. 100 mg/kg over 16 hours). Higher ongoing infusion rates (e.g. 200 mg/kg over 16 hours) may be required for massive paracetamol ingestions and a clinical toxicologist should be consulted.**

#Acetylcysteine is also compatible with 0.45% saline + 5% dextrose.

<sup>^</sup>For adults (age ≥ 14 y) dosing should be based on actual bodyweight rounded up to the nearest 10 kg, with a ceiling weight of 110 kg. For children (age < 14 y) use actual body weight.

\* If the initial paracetamol concentration was **more than double the nomogram line** following an acute ingestion increase acetylcysteine dose to 200 mg/kg (maximum 22 g) in glucose 5% 1000 mL (child 14 mL/kg up to 1000 mL) or sodium chloride 0.9% 1000 mL (child 14 mL/kg up to 1000 mL) intravenously, over 16 hours.

**Note:** Monitoring with pulse oximetry for the first 2 hours of the infusion is recommended.

**Box 4: Dose and volume of acetylcysteine to be charted for each infusion, based on actual bodyweight in adults.**

- Obtain weight of patient (kg) to determine dosage. Dosing should be based on actual body weight rounded up to the nearest 10 kg, with a ceiling weight of 110 kg.
- Acetylcysteine is packaged for intravenous infusion in ampoules, each containing a 20% solution (i.e. 200 mg acetylcysteine per 1 mL)
- Remove the corresponding volume from the infusion fluid (i.e. 5 % glucose or sodium chloride 0.9%) then add acetylcysteine. Invert all prepared solutions at least 10 times prior to infusing to ensure adequate mixing.
- Acetylcysteine is also compatible with 0.45% saline + 5% dextrose.

PATIENT'S BODY WEIGHT (kg)	INITIAL INFUSION (200 mg/kg of acetylcysteine)	SECOND (100 mg/kg of acetylcysteine)
	Dose (g) & Volume (mL) of acetylcysteine to be added to 500 mL of 5% glucose or sodium chloride 0.9%	Dose (g) & Volume (mL) of acetylcysteine to be added to 1000 mL of 5% glucose or sodium chloride 0.9%
50	10 g = 50 mL	5 g = 25 mL
60	12 g = 60 mL	6 g = 30 mL
70	14 g = 70 mL	7 g = 35 mL
80	16 g = 80 mL	8 g = 40 mL
90	18 g = 90 mL	9 g = 45mL
100	20 g = 100 mL	10 g = 50 mL
110 (maximum dose)	22 g = 110 mL	11 g = 55 mL

**Box 5: Cessation of Acetylcysteine**

In those patients who require acetylcysteine beyond 20 hours. Acetylcysteine can be ceased if **all** the following criteria have been met:

- ALT or AST are decreasing
- INR < 2.0
- Patient clinically well

**AND**

For modified-release ingestions and those with an initial paracetamol concentration greater than double the nomogram line: paracetamol concentration < 10 mg/L (66 µmol/L)

## Hepatotoxicity and Subsequent Liver Failure:

Only a small proportion of patients develop hepatotoxicity (ALT > 1000 U/L); early symptoms include nausea, vomiting, abdominal pain and right upper quadrant tenderness. Of these only a minority will develop fulminant hepatic failure, and most patients recover fully with standard treatments [10, 15, 61]. Typically, in those with paracetamol induced acute liver injury the ALT and AST will rise for 3 - 4 days before recovering [62]. Acetylcysteine is continued until the criteria met in [Box 5](#). Investigations that monitor liver function and guide prognosis should be performed regularly in all patients with hepatotoxicity, including electrolytes, urea, creatinine, liver function tests, INR, blood sugar, phosphate and venous blood gas (looking at the pH and lactate).

A Liver Transplant Unit should be consulted if any of the following criteria are met:

- INR > 3.0 at 48 hours or > 4.5 at any time,
- oliguria or creatinine > 200  $\mu\text{mol/L}$ ,
- persistent acidosis (pH < 7.3) or arterial lactate > 3 mmol/L,
- systolic hypotension with BP < 80mmHg, despite resuscitation,
- hypoglycaemia, severe thrombocytopenia or encephalopathy of any degree,
- or any alteration of consciousness (GCS < 15) not associated with sedative co-ingestions.

DO NOT GIVE clotting factors unless bleeding or after discussion with a Liver Transplant Unit.

*GRADE: Strong; Evidence: Strong.*

## Intravenous paracetamol medication errors:

Intravenous paracetamol medication errors are not dealt within these guidelines, as the treatment thresholds are lower than for an oral ingestion [63]. The most common are iatrogenic and due to ten-fold calculation errors in children [64]. A clinical toxicologist or Poisons Information Centre should be contacted regarding these cases.

## Recommendations on when to seek further advice from Poisons Information Centre\*

- Very large overdoses: immediate release or modified release paracetamol overdoses of  $\geq 50$  g or 1 g/kg (whichever is less).
- High paracetamol concentration, more than triple the nomogram line.
- Intravenous paracetamol errors/overdoses, as the treatment threshold is lower.
- Patients with hepatotoxicity (i.e. ALT > 1000 IU/L).
- Neonatal paracetamol poisonings

**Note:** These are situations where the risk of hepatotoxicity and complications are greater, the optimum advice is potentially changing, and where it may be most useful to seek advice.

\* For Poisons Information Centre: Call 131126 in Australia OR 0800 764766 in New Zealand

## Conclusion:

This is an up dated 2019 guideline for the management of paracetamol poisoning in Australia and New Zealand. While most paracetamol poisoning scenarios are covered, if there are any concerns regarding the management of paracetamol ingestion advice can always be sought from a clinical toxicologist or Poisons Information Centre (131126 in Australia, 0800 764766 in New Zealand).

## References

1. Fontana RJ. Acute liver failure including acetaminophen overdose. *Med Clin North Am* 2008; 92(4): 761-94, viii.
2. Lancaster EM, Hiatt JR, Zarrinpar A. Acetaminophen hepatotoxicity: an updated review. *Arch Toxicol* 2015; 89(2): 193-9.
3. Huynh A, Cairns R, Brown JA, et al. Patterns of poisoning exposure at different ages: the 2015 annual report of the Australian Poisons Information Centres. *Med J Aus* 2018; 209(2): 74-9.
4. Paracetamol poisoning [revised 2020 April]. In: eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2020 April. <https://www.tg.org.au/>
5. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. *Clin Pharmacokinet* 1982; 7(2): 93-107.
6. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. *Br J Clin Pharmacol* 1980; 10 Suppl 2: 291s-8s.
7. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. *J Pharmacol Exp Ther* 1973; 187(1): 211-7.
8. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. *Clin Pharmacol Ther* 1974; 16(4): 676-84.
9. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. *Handb Exp Pharmacol* 2010; (196): 369-405.
10. Chiew AL, Glud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. *Cochrane Database of Systematic Reviews* 2018; (2): Art. No.: CD003328.
11. Owens KH, Medicott NJ, Zacharias M, Whyte IM, Buckley NA, Reith DM. Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio. *Clin Exp Pharmacol Physiol* 2015; 42(1): 102-8.
12. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. *Ther Drug Monit* 2000; 22(6): 742-8.
13. Jang DH, Weaver MD, Pizon AF. In vitro study of N-acetylcysteine on coagulation factors in plasma samples from healthy subjects. *Clin Toxicol (Phila)*. 2013; 9(1): 49-53.
14. Daly FFS, Fountain JS, Murray L, Graudins A, Buckley NA. Guidelines for the management of paracetamol poisoning in Australia and New Zealand - Explanation and elaboration. *Med J Aust* 2008; 188(5): 296-301.
15. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). *N Engl J Med* 1988; 319(24): 1557-62.
16. Bateman DN, Carroll R, Pettie J, et al. Effect of the UK's revised paracetamol poisoning management guidelines on

- admissions, adverse reactions and costs of treatment. *Br J Clin Pharmacol* 2014; 78(3): 610-8.
17. Bateman DN, Dear JW, Carroll R, et al. Impact of reducing the threshold for acetylcysteine treatment in acute paracetamol poisoning: the recent United Kingdom experience. *Clin Toxicol (Phila)* 2014; 52(8): 868-72.
  18. Shah AD, Wood DM, Dargan PI. Understanding lactic acidosis in paracetamol (acetaminophen) poisoning. *Br J Clin Pharmacol* 2011; 71(1): 20-8.
  19. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. *Clin Toxicol (Phila)* 1999; 37(6): 753-7.
  20. Duffull SB, Isbister GK. Predicting the requirement for N-acetylcysteine in paracetamol poisoning from reported dose. *Clin Toxicol (Phila)* 2013; 51(8): 772-6.
  21. Chiew AL, Isbister GK, Kirby KA, Page CB, Chan BSH, Buckley NA. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2). *Clin Toxicol (Phila)* 2017; 55(10): 1055-65.
  22. Chiew AL, Isbister GK, Page CB, Kirby KA, Chan BSH, Buckley NA. Modified release paracetamol overdose: a prospective observational study (ATOM-3). *Clin Toxicol (Phila)* 2018; 56(9): 810-9.
  23. Salmonson H, Sjöberg G, Brogren J. The standard treatment protocol for paracetamol poisoning may be inadequate following overdose with modified release formulation: a pharmacokinetic and clinical analysis of 53 cases. *Clin Toxicol (Phila)* 2018; 56(1): 63-8.
  24. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? *J Toxicol Clin Toxicol* 1999; 37(6): 759-67.
  25. Graudins A. Paracetamol poisoning in adolescents in an Australian setting: Not quite adults. *Emerg Med Australas* 2015 Apr; 27(2):139-44.
  26. Marks DJB, Dargan PI, Archer JRH, et al. Outcomes from massive paracetamol overdose: a retrospective observational study. *Br J Clin Pharmacol* 2017; 83(6): 1263-72.
  27. Cairney DG, Beckwith HK, Al-Hourani K, Eddleston M, Bateman DN, Dear JW. Plasma paracetamol concentration at hospital presentation has a dose-dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. *Clin Toxicol (Phila)* 2016; 54(5): 405-10.
  28. Doyon S, Klein-Schwartz W. Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose. *Academic emergency medicine : official journal of the Society for Acad. Emerg. Med* 2009; 16(1): 34-9.
  29. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. *Clin Toxicol (Phila)* 2012; 50(2): 91-8.
  30. Hendrickson RG. What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose? *Clin Toxicol (Phila)* 2019; 57(8): 686-91.
  31. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. *Clin Toxicol (Phila)* 2002; 40(1): 3-20.
  32. Doyon S, Klein-Schwartz W. Hepatotoxicity Despite Early Administration of Intravenous N-Acetylcysteine for Acute Acetaminophen Overdose. *Acad Emerg Med* 2009; 16(1): 34-9.
  33. Graudins A, Chiew A, Chan B. Overdose with modified-release paracetamol results in delayed and prolonged absorption of paracetamol. *Intern Med J* 2010; 40(1): 72-6.
  34. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. *Pediatrics* 1975 Jun; 55(6): 871-6.
  35. Anderson BJ, Holford NH, Armishaw JC, Aicken R. Predicting concentrations in children presenting with acetaminophen overdose. *J Pediatr* 1999; 135(3): 290-5.
  36. Prescott LF. Therapeutic misadventure with paracetamol: fact or fiction? *Am J Ther* 2000; 7(2): 99-114.
  37. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. *JAMA* 2006; 296(1): 87-93.
  38. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity--where do we go from here? *Expert Opin Drug Saf* 2007; 6(4): 341-55.
  39. Kalsi SS, Dargan PI, Waring WS, Wood DM. A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose. *Open Access Emerg Med* 2011; 3: 87-96.
  40. Daly FF, O'Malley GF, Heard K, Bogdan GM, Dart RC. Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion. *Ann Emerg Med* 2004; 44(4): 393-8.
  41. Egan H, Isbister GK, Robinson J, et al. Retrospective evaluation of repeated supratherapeutic ingestion (RSTI) of paracetamol (dagger). *Clin Toxicol (Phila)* 2019; 57(8): 703-11.
  42. Acheampong P, Thomas SH. Determinants of hepatotoxicity after repeated supratherapeutic paracetamol ingestion: systematic review of reported cases. *Br J Clin Pharmacol* 2016; 82(4): 923-31.
  43. Wong A, Gunja N, McNulty R, Graudins A. Analysis of an 8-hour acetylcysteine infusion protocol for repeated supratherapeutic ingestion (RSTI) of paracetamol. *Clin Toxicol (Phila)* 2018; 56(3): 199-203.
  44. Hamlyn AN, Lesna M, Record CO, et al. Methionine and cysteamine in paracetamol (acetaminophen) overdose, prospective controlled trial of early therapy. *J Int Med Res* 1981; 9(3): 226-31.
  45. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. *BMJ (Clinical research ed)* 1991; 303(6809): 1026-9.
  46. Chiew AL, Isbister GK, Duffull SB, Buckley NA. Evidence for the changing regimens of acetylcysteine. *Br J Clin Pharmacol* 2016; 81(3): 471-81.
  47. Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. *Lancet (London, England)* 2014; 383(9918): 697-704.
  48. Wong A, Graudins A. Simplification of the standard three-bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. *Clin Toxicol (Phila)* 2016; 54(2): 115-9.
  49. Isbister GK, Downes MA, McNamara K, Berling I, Whyte IM, Page CB. A prospective observational study of a novel 2-phase infusion protocol for the administration of acetylcysteine in paracetamol poisoning. *Clin Toxicol (Phila)* 2016; 54(2): 120-6.
  50. McNulty R, Lim JME, Chandru P, Gunja N. Fewer adverse effects with a modified two-bag acetylcysteine protocol in paracetamol overdose. *Clin Toxicol (Phila)* 2018; 56(7): 618-21.
  51. Pettie JM, Caparrotta TM, Hunter RW, et al. Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. *EClinicalMedicine* 2019; 11: 11-7.



52. Wong A, Isbister GK, McNulty R, et al. Abstract: Efficacy of a two bag acetylcysteine regimen to treat paracetamol overdose, 39th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 21-24 May 2019, Naples, Italy. *Clin Toxicol (Phila)* 2019; 57(6): 423-602.
53. Schmidt LE, Rasmussen DN, Petersen TS, et al. Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose. *Clin Toxicol (Phila)* 2018; 56(11): 1128-34.
54. Ferner RE, Langford NJ, Anton C, Hutchings A, Bateman DN, Routledge PA. Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. *Br J Clin Pharmacol* 2001; 52(5): 573-7.
55. Duncan R. New recommendation for N-acetylcysteine dosing may reduce incidence of adverse effects. *Emerg Med J* 2006 Jul 1; 23(7): 584.
56. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. *Clin Toxicol (Phila)* 2009; 47(2): 81-8.
57. Kao LW, Kirk MA, Furbee RB, Mehta NH, Skinner JR, Brizendine EJ. What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning? *Ann Emerg Med* 2003; 42(6): 741-50.
58. Lynch RM, Robertson R. Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study. *Emerg Nurse*. 2004; 12(1): 10-5.
59. Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. *Ann Emerg Med* 1998; 31(6): 710-5.
60. Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. *Br J Clin Pharmacol* 2001; 51(1): 87-91.
61. Cairns R, Brown JA, Wylie CE, Dawson AH, Isbister GK, Buckley NA. Paracetamol poisoning in Australia, 2004-2017: an analysis of overdose frequency, overdose size, liver injury and deaths. *Med J Aust* 2019; *Med J Aust* 2019; 211 (5):218-223.
62. Green TJ, Sivilotti ML, Langmann C, et al. When do the aminotransferases rise after acute acetaminophen overdose? *Clin Toxicol (Phila)* 2010; 48(8): 787-92.
63. Gray T, Hoffman RS, Bateman DN. Intravenous paracetamol – an international perspective of toxicity. *Clin Toxicol (Phila)* 2011; 49(3): 150-2.
64. Berling I, Anscombe M, Isbister GK. Intravenous paracetamol toxicity in a malnourished child. *Clin Toxicol (Phila)* 2012; 50(1): 74-6.